TP53 and neoplasm: To verify whether there is a correlation between clinicopathological features and risk scores associated with the m6A-LPS model, we performed the Wilcoxon test and Kruskal–Wallis test, and the results showed that BRCA patients with younger age, higher American Joint Committee on Cancer (AJCC) (23) stage level and TMB, lower immune score and tumor purity, mutation type of TP53, wild-type PIK3CA, and Cluster 2 of m6A-related lncRNA genotypic subgroup had higher risk scores (Figures 4A–H), whereas the mutation status of BRCA1/2 did not correlate with the risk score (Figure 4J).